Alex Rosen
Direttore/Membro del Consiglio presso Upstream Bio, Inc.
Profilo
Alex Rosen is currently working as a Director at Upstream Bio, Inc. Prior to this, he worked as a Biotech Investor at Venrock Associates.
Mr. Rosen holds a doctorate degree from the University of Pennsylvania, an undergraduate degree from Princeton University, and an MBA from The Wharton School of the University of Pennsylvania.
Posizioni attive di Alex Rosen
| Società | Posizione | Inizio |
|---|---|---|
Upstream Bio, Inc.
 Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | Direttore/Membro del Consiglio | 08/06/2023 |
Precedenti posizioni note di Alex Rosen
| Società | Posizione | Fine |
|---|---|---|
Venrock Associates
 Venrock Associates Investment ManagersFinance Venrock Associates is an Independent Venture Capital firm founded in 1969. The firm is headquartered in Palo Alto. | Investitore di Private Equity | - |
Formazione di Alex Rosen
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
| University of Pennsylvania | Doctorate Degree |
| Princeton University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 2 |
|---|---|
Venrock Associates
Venrock Associates Investment ManagersFinance Venrock Associates is an Independent Venture Capital firm founded in 1969. The firm is headquartered in Palo Alto. | Finance |
Upstream Bio, Inc.
Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | Commercial Services |
- Borsa valori
- Insiders
- Alex Rosen
